Coexistence of fluorescent Escherichia coli strains in millifluidic droplets reactors

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Xinne Zhao ◽  
Rico Illing ◽  
Philip Ruelens ◽  
Michael Bachmann ◽  
Gianaurelio Cuniberti ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Clinical Importance ◽  
Competition And Cooperation ◽  
Species Evolution

Understanding competition and cooperation within microbiota is of high fundamental and clinical importance, helping to comprehend species’ evolution and biodiversity. We co-encapsulated and cultured two isogenic Escherichia coli strains expressing...

scholarly journals Genomic analysis and clinical importance of Escherichia coli isolate from patients with sepsis

2015 ◽  
Vol 58 (1) ◽  
pp. 22 ◽  
Author(s):  
Arindam Chakraborty ◽  
Prabha Adhikari ◽  
Shalini Shenoy ◽  
Vishwas Saralaya
Keyword(s):  
Escherichia Coli ◽  
Clinical Importance ◽  
Genomic Analysis ◽  
Coli Isolate

scholarly journals In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella Typhimurium and Escherichia coli

2019 ◽  
Author(s):  
Md. Akil Hossain ◽  
Hae-Chul Park ◽  
Kwang-jick Lee ◽  
Sung-Won Park ◽  
Seung-Chun Park ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Synergistic Effects ◽  
Clinical Importance ◽  
Blood Stream ◽  
In Vitro Cytotoxicity ◽  
Farm Animals ◽  
Epicatechin Gallate ◽  
E Coli

Abstract Background: The antibiotics generally used in farm animals are rapidly losing their effectiveness all over the world as bacteria develop antibiotic resistance. New strategies are needed to block the development of resistance and to prolong the life of traditional antibiotics. This study aimed to increase the efficacy of existing antibiotics by combining them with the opportunistic phenolic compounds gallic acid (GA), epicatechin, epicatechin gallate, epigallocatechin and hamamelitannin. Fractional inhibitory concentration index (FICI) of phenolic compound-antibiotic combinations against Salmonella enterica serovar Typhimurium (S. Typhimurium) and Escherichia coli (E. coli) were determined. Based on the FICI and clinical importance, 3 combinations were selected to evaluate their effects on the virulence factors of these bacteria. The in vitro cytotoxicity of GA and hamamelitannin in Rattus norvegicus (IEC-6) cell lines were evaluated. Results: Minimum inhibitory concentrations (MICs) of epigallocatechin, GA and hamamelitannin found against different strains were (512–1024), (256–1024) and (512–2048) μg/mL, respectively. Synergistic effects were obtained from combinations of thiamphenicol-GA (FICI: 0.28), erythromycin-hamamelitannin (FICI: 0.38) and thiamphenicol-hamamelitannin (FICI: 0.50) against E. coli, and erythromycin-epicatechin gallate (FICI: 0.50) against S. Typhimurium. Moreover, additive effects were obtained from 33 combinations against S. Typhimurium (FICI: 0.502~0.750) and E. coli (FICI: 0.502~0.625). The time-kill assays and ultrastructural morphology showed that GA-ceftiofur, and hamamelitannin-erythromycin and GA-ampicillin combinations more efficiently inhibited the growth of S. Typhimurium and E. coli, respectively, compared to individual antibiotics. Biofilm viability and swimming and swarming motilities of S. Typhimurium in presence of GA-ceftiofur, and E. coli in presence of hamamelitannin-erythromycin and GA-ampicillin combinations were more competently inhibited than individual antimicrobials. The inhibitory concentrations 50% (IC50) of GA and hamamelitannin in IEC-6 cells were 564.55 μM and 988.54 μM, respectively. Conclusions: This study suggest that GA-ceftiofur combination can be potential medication to treat S. Typhimurium-associated diarrhea and prevent S. Typhimurium-associated blood-stream infections (e.g.: fever) in farm animals. Hamamelitannin-erythromycin and GA-ampicillin combinations can be effective in restricting E. coli contamination in farm animals, and ultimately its transmission from animal to human. Further study to confirm these effects and safety profiles in in vivo system should be undertaken for establishing these combinations as medications.

Antibacterial Activity of the Silver Nanoparticles against Escherichia coli and Enterobacter sp

2017 ◽  
Vol 1 (1) ◽  
Author(s):  
Kathirvel Maruthai ◽  
Kommoju Vallayyachari ◽  
Thirumurugan Ravibalan ◽  
Sheryl Ann Philip ◽  
Antony V. Samrot ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Chemical Method ◽  
Reduction Method ◽  
Clinical Importance ◽  
Bactericidal Effect ◽  
Bacterial Cells ◽  
E Coli ◽  
Protein Leakage ◽  
Glucose Reduction ◽  
Membrane Destabilization

In this study, spherical silver nanoparticle (AgNP) was produced by sustainable chemical method i.e. glucose reduction method and it was utilized to analyse the bactericidal effect against the pathogens of clinical importance - E. coli (ATCC 10536) and Enterobacter sp., KL46 by membrane destabilization and protein leakage analyses. Minimum inhibitory/bactericidal and antibiogram analyses reported that 20ng/ml was enough to inhibit/kill bacterial cells. Even 20ng/ml concentration of AgNPs was found to destabilize membrane and lead to protein leakage from bacterial cells. 

scholarly journals Evaluating the Occurrence of Escherichia albertii in Chicken Carcass Rinses by PCR, Vitek Analysis, and Sequencing of therpoBGene

2014 ◽  
Vol 81 (5) ◽  
pp. 1727-1734 ◽  
Author(s):  
Rebecca L. Lindsey ◽  
Paula J. Fedorka-Cray ◽  
Melanie Abley ◽  
Jennifer B. Turpin ◽  
Richard J. Meinersmann
Keyword(s):  
Escherichia Coli ◽  
Causative Agent ◽  
Clinical Importance ◽  
Culture Methods ◽  
Hafnia Alvei ◽  
Content Type ◽  
Shiga Toxins ◽  
Heat Stable ◽  
Food Borne ◽  
Chicken Carcass

ABSTRACTEscherichia albertiiis a recently described species that has been associated with gastroenteritis in humans and with healthy and ill birds. Most recently, it has been identified as the causative agent in a food-borne outbreak in Japan. The distribution and clinical importance ofE. albertiiare not well studied because its importance is unclear. Culture methods for clinical isolation frequently missE. albertiior incorrectly identify it asShigellaspp.,Escherichia coli, orHafnia alvei. This study was designed to determine ifE. albertiicould be recovered from chicken carcass rinses collected at slaughter during a 1-year period from November 2009 until October 2010. Colonies were isolated from chicken carcass rinses and tested by PCR for the presence or absence ofclpX, lysP, mdh, intimin (eae), Shiga toxins 1 and 2 (stx1,stx2, andstx2f), heat-stable enterotoxin A (staA), and cytolethal distending toxins 1 and 2 (cdtB) genes. Sixty-five isolates were analyzed by sequencing a section of therpoBgene. Analysis of therpoBgene sequences revealed 14 fixed differences betweenE. albertiiand other, closely related organisms. The fixed differences found in therpoBgene could aid in future discrimination ofE. albertiifrom closely related bacteria.

Detection of a lactobacillus substance that inhibits Escherichia coli

1988 ◽  
Vol 34 (8) ◽  
pp. 974-978 ◽  
Author(s):  
Jacqueline A. McGroarty ◽  
Gregor Reid
Keyword(s):  
Escherichia Coli ◽  
Molecular Weight ◽  
Lactobacillus Acidophilus ◽  
Lactobacillus Casei ◽  
Clinical Importance ◽  
Inhibitory Effect ◽  
Prevention Of Infection ◽  
E Coli ◽  
Bioactive Substance ◽  
Uropathogenic Bacteria

Recent studies have shown that certain lactobacilli strains have the ability to interfere with the adherence and growth of uropathogenic bacteria. This interaction is believed to be important in the maintenance of a normal urogenital flora and in the prevention of infection in females. In the present study, Lactobacillus casei ssp. rhamnosus GR-1 and Lactobacillus acidophilus 76 were found to exert an inhibitory effect on pyelonephritogenic mutant Escherichia coli Hu 734 and E. coli ATCC 25922. The bioactivity of the inhibitor produced by strain GR-1 was retained under pH buffered conditions and was bactericidal. The bioactive substance was heat labile, not precipitated by up to 80% ammonium sulphate, and extractable in chloroform. The data indicated that the inhibitor is not lactic acid or hydrogen peroxide and has a molecular weight greater than 12 000 – 14 000. Human urine supported production of the inhibitor and reduced and delayed outgrowth of the E. coli. The ability of L. casei GR-1 and possibly other lactobacilli strains to produce inhibitors of uropathogenic bacteria may have clinical importance and significance in the microbial ecology of the urogenital tract.

scholarly journals Class D β-Lactamases: Are They All Carbapenemases?

2014 ◽  
Vol 58 (4) ◽  
pp. 2119-2125 ◽  
Author(s):  
Nuno T. Antunes ◽  
Toni L. Lamoureaux ◽  
Marta Toth ◽  
Nichole K. Stewart ◽  
Hilary Frase ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Clinical Importance ◽  
Kinetic Studies ◽  
Resistance Pattern ◽  
Content Type ◽  
Narrow Spectrum ◽  
Class D ◽  
Life Threatening

ABSTRACTCarbapenem-hydrolyzing class D β-lactamases (CHDLs) are enzymes of the utmost clinical importance due to their ability to produce resistance to carbapenems, the antibiotics of last resort for the treatment of various life-threatening infections. The vast majority of these enzymes have been identified inAcinetobacterspp., notably inAcinetobacter baumannii. The OXA-2 and OXA-10 enzymes predominantly occur inPseudomonas aeruginosaand are currently classified as narrow-spectrum class D β-lactamases. Here we demonstrate that when OXA-2 and OXA-10 are expressed inEscherichia colistrain JM83, they produce a narrow-spectrum antibiotic resistance pattern. When the enzymes are expressed inA. baumanniiATCC 17978, however, they behave as extended-spectrum β-lactamases and confer resistance to carbapenem antibiotics. Kinetic studies of OXA-2 and OXA-10 with four carbapenems have demonstrated that their catalytic efficiencies with these antibiotics are in the same range as those of some recognized class D carbapenemases. These results are in disagreement with the classification of the OXA-2 and OXA-10 enzymes as narrow-spectrum β-lactamases, and they suggest that other class D enzymes that are currently regarded as noncarbapenemases may in fact be CHDLs.

scholarly journals Faecal colonization with P-fimbriated Escherichia coli between 0 and 18 months of age

1988 ◽  
Vol 100 (2) ◽  
pp. 185-191 ◽  
Author(s):  
K. Tullus ◽  
Gunilla Källenius ◽  
R. Möllby
Keyword(s):  
Escherichia Coli ◽  
Breast Feeding ◽  
Bacterial Species ◽  
Clinical Importance ◽  
Colonization Rate ◽  
E Coli ◽  
Healthy Infants ◽  
Pure Cultures ◽  
A Prospective Study ◽  
Breast Fed

SUMMARYA prospective study of faecal colonization with P-fimbriated Escherichia coli between 0 and 18 months of ago was conducted in 751 healthy infants. The influence of breast-feeding and treatment with antibiotics on this colonization was studied. Colonization with P-fimbriatcd E. coli increased with age from 10% at 6 days to 30% at 18 months of ago (P < 0·01). Breast-feeding influenced colonization at 6 weeks of age when breast-fed children harboured fewer bacterial species (P < 0·001) and fewer P-fimbriated E. coli (P = 0·06) than bottle-fed infants. Treatment with antibiotics increased the colonization rate with P-fimbriatcd E. coli at the age of 11 months (P < 0·05). However, this was not true for treatment with ampicillin, which increased colonization rate with Gram-negative species other than E. coli (P < 0·05). Fifty per cent (378) of all children were colonized and a quarter (183) had pure cultures of P-fimbriatcd E. coli in at least one faecal sample. The clinical importance of this colonization remains to be shown.

scholarly journals In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella Typhimurium and Escherichia coli

2019 ◽  
Author(s):  
Md. Akil Hossain(Former Corresponding Author) ◽  
Hae-Chul Park ◽  
Kwang-jick Lee ◽  
Sung-Won Park ◽  
Seung-Chun Park ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Phenolic Compound ◽  
Clinical Importance ◽  
In Vitro Cytotoxicity ◽  
Hep G2 ◽  
E Coli ◽  
Development Of Resistance ◽  
Different Strains

Abstract Background: Bacteria have remarkable abilities to acquire resistance against antibiotics by several mechanisms. New strategies are needed to block the development of resistance and to prolong the life of traditional antibiotics. This study aimed to increase the efficacy of existing antibiotics by combining them with the opportunistic phenolic compound gallic acid (GA) and its derivatives. Fractional inhibitory concentration (FIC) indexes of phenolic compound-antibiotic combinations against Salmonella enterica serovar Typhimurium ( S. Typhimurium) and Escherichia coli ( E. coli ) were determined. Based on the FIC index values and clinical importance, 3 combinations were selected to evaluate their effects on the virulence factors of these bacteria. The in vitro cytotoxicity of GA and hamamelitannin in human (Hep G2) and Rattus norvegicus (IEC-6) cell lines were evaluated. Results: Phenolic compounds demonstrated considerable antibacterial effects as the minimum inhibitory concentrations (MICs) of epigallocatechin, GA and hamamelitannin found against different strains were (512–1024), (256–1024) and (512–2048) μg/mL, respectively. The FIC indexes of the combined antibacterials against these strains were 0.281–1.016. The time-kill assays and ultrastructural morphology showed that the GA-ceftiofur combination, and hamamelitannin-erythromycin and GA-ampicillin combinations more efficiently inhibited the growth of S. Typhimurium and E. coli , respectively, compared to the individual antibiotics. Biofilm viability and the swimming and swarming motilities of S. Typhimurium in the presence of GA-ceftiofur and E. coli in the presence of the hamamelitannin-erythromycin and GA-ampicillin combinations were more competently inhibited than individual antimicrobials. The inhibitory concentrations 50% (IC 50 ) of GA and hamamelitannin in Hep G2 cells were 1427.34 μM and 2024.97 μM, and in IEC-6 cells were 564.55 μM and 988.54 μM, respectively. Conclusions: We can conclude that these antibacterial combinations can be potential medications to treat S. Typhimurium and E. coli infections. Further study to confirm this effect in in vivo system and to determine the precise mechanism of action should be undertaken to establish these combinations as medications.

scholarly journals In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella Typhimurium and Escherichia coli

2020 ◽  
Author(s):  
Md. Akil Hossain ◽  
Hae-Chul Park ◽  
Kwang-jick Lee ◽  
Sung-Won Park ◽  
Seung-Chun Park ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Synergistic Effects ◽  
Clinical Importance ◽  
Blood Stream ◽  
Farm Animals ◽  
Epicatechin Gallate ◽  
E Coli ◽  
Development Of Resistance

Abstract Background: The antibiotics generally used in farm animals are rapidly losing their effectiveness all over the world as bacteria develop antibiotic resistance. New strategies are needed to block the development of resistance and to prolong the life of traditional antibiotics. This study aimed to increase the efficacy of existing antibiotics by combining them with the opportunistic phenolic compounds gallic acid (GA), epicatechin, epicatechin gallate, epigallocatechin and hamamelitannin. Fractional inhibitory concentration index (FICI) of phenolic compound-antibiotic combinations against Salmonella enterica serovar Typhimurium (S. Typhimurium) and Escherichia coli (E. coli) were determined. Based on the FICI and clinical importance, 3 combinations (GA-ampicillin, GA-ceftiofur and hamamelitannin-erythromycin) were selected to evaluate their effects on the virulence factors of these bacteria. Viabilities of Rattus norvegicus (IEC-6) cell in presence of these combination antibacterials were evaluated.Results: Minimum inhibitory concentrations (MICs) of epigallocatechin, GA and hamamelitannin found against different strains were (512–1024), (256–1024) and (512–2048) μg/mL, respectively. Synergistic effects were obtained from combinations of thiamphenicol-GA (FICI: 0.28), erythromycin-hamamelitannin (FICI: 0.38) and thiamphenicol-hamamelitannin (FICI: 0.50) against E. coli, and erythromycin-epicatechin gallate (FICI: 0.50) against S. Typhimurium. Moreover, additive effects were obtained from 33 combinations against S. Typhimurium (FICI: 0.502~0.750) and E. coli (FICI: 0.502~0.625). The time-kill assays and ultrastructural morphology showed that GA-ceftiofur, and hamamelitannin-erythromycin and GA-ampicillin combinations more efficiently inhibited the growth of S. Typhimurium and E. coli, respectively, compared to individual antibiotics. Biofilm viability and swimming and swarming motilities of S. Typhimurium in presence of GA-ceftiofur, and E. coli in presence of hamamelitannin-erythromycin and GA-ampicillin combinations were more competently inhibited than individual antimicrobials. Viabilities of IEC-6 cells were significantly enhanced by GA-ceftiofur, GA-ampicillin combinations than these antibacterials alone. Conclusions: This study suggest that GA-ceftiofur combination can be potential medication to treat S. Typhimurium-associated diarrhea and prevent S. Typhimurium-associated blood-stream infections (e.g.: fever) in farm animals. Hamamelitannin-erythromycin and GA-ampicillin combinations can be effective in restricting E. coli contamination in farm animals, and ultimately its transmission from animal to human. Further in vivo study to confirm these effects and safety profiles in farm animal should be undertaken for establishing these combinations as medications.

scholarly journals Genomic epidemiology and evolution of Escherichia coli in wild animals

2020 ◽  
Author(s):  
Robert Murphy ◽  
Martin Palm ◽  
Ville Mustonen ◽  
Jonas Warringer ◽  
Anne Farewell ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Population Structure ◽  
Host Species ◽  
Bacterial Species ◽  
Clinical Importance ◽  
Wild Animal ◽  
Whole Genome ◽  
Wild Animals ◽  
E Coli ◽  
Wild Hosts

AbstractEscherichia coli is a common bacterial species in the gastrointestinal tracts of warm-blooded animals and humans. Pathogenic and antimicrobial resistance in E. coli may emerge via host switching from animal reservoirs. Despite its potential clinical importance, knowledge of the population structure of commensal E. coli within wild hosts and the epidemiological links between E. coli in non-human hosts and E. coli in humans is still scarce. In this study, we analysed the whole genome sequencing data of a collection of 119 commensal E. coli recovered from the guts of 68 mammal and bird species in Mexico and Venezuela in the 1990s. We observed low concordance between the population structures of E. coli colonizing wild animals and the phylogeny, taxonomy and ecological and physiological attributes of the host species, with distantly related E. coli often colonizing the same or similar host species and distantly related host species often hosting closely related E. coli. We found no evidence for recent transmission of E. coli genomes from wild animals to either domesticated animals or humans. However, multiple livestock- and human-related virulence factor genes were present in E. coli of wild animals, including virulence factors characteristic for Shiga toxin-producing E. coli (STEC) and atypical enteropathogenic E. coli (aEPEC), where several isolates from wild hosts harboured the locus of enterocyte effacement (LEE) pathogenicity island. Moreover, E. coli in wild animal hosts often harboured known antibiotic resistance determinants, including against ciprofloxacin, aminoglycosides, tetracyclines and beta-lactams, with some determinants present in multiple, distantly related E. coli lineages colonizing very different host animals. We conclude that although the genome pools of E. coli colonizing wild animal and human gut are well separated, they share virulence and antibiotic resistance genes and E. coli underscoring that wild animals could serve as reservoirs for E. coli pathogenicity in human and livestock infections.ImportanceEscherichia coli is a clinically importance bacterial species implicated in human and livestock associated infections worldwide. The bacterium is known to reside in the guts of humans, livestock and wild animals. Although wild animals are recognized to serve as potential reservoirs for pathogenic E. coli strains, the knowledge of the population structure of E. coli in wild hosts is still scarce. In this study we used the fine resolution of whole genome sequencing to provide novel insights into the evolution of E. coli genomes within a broad range of wild animal species (including mammals and birds), the co-evolution of E. coli strains with their hosts and the genetics of pathogenicity of E. coli strains in wild hosts. Our results provide evidence for the clinical importance of wild animals as reservoirs for pathogenic strains and necessitate the inclusion of non-human hosts in the surveillance programs for E. coli infections.

Sign in / Sign up

Export Citation Format

Share Document